Medicare Denied Prescription Drug (Part D)

What This Means

A Part D refusal is a coverage determination, and the rule that decides most cases is the exception standard in 42 CFR 423.578: your plan can cover a drug that is off its formulary — or blocked by prior authorization, step therapy, or a quantity limit — when your prescriber states that the covered alternatives would not be as effective for you or would cause adverse effects. Once the plan has that supporting statement it must decide within 72 hours, or 24 hours if your prescriber says waiting could seriously harm your health (42 CFR 423.568, 423.572). Do one thing now: call your prescriber’s office and ask them to send your plan an exception request with a supporting statement — the decision clock does not start until the plan receives it.

If you already hold a written denial from the plan, you have 65 days from the date on that notice to ask the plan for a redetermination (Medicare.gov). If you were turned away at the pharmacy counter instead, the pharmacist should have handed you a notice titled “Medicare Drug Coverage and Your Rights” (CMS-10147), which explains how to ask your plan for that written decision (CMS) — a pharmacy rejection is not yet a denial you can appeal.

Why This Happens

• The drug is not on your plan’s formulary. Every Part D plan has a list of covered drugs called a formulary. If your drug isn’t on the list, the plan won’t cover it unless you get a formulary exception (Medicare.gov drug plan rules).
• Prior authorization was required. Your plan requires advance approval for certain drugs. If your doctor prescribed the drug without getting prior authorization, the pharmacy claim will be denied.
• Your prior authorization expired. Plan approvals are granted for a limited period, and neither the plan nor the prescriber automatically renews one — you usually find out at the pharmacy counter when a refill is rejected. Ask your doctor’s office to submit a renewal right away, and ask your plan or pharmacist whether a short supply can be filled while it is processed.
• Step therapy requirements weren’t met. Your plan requires you to try a less expensive or preferred drug first. If you haven’t tried the required drug (or your plan doesn’t have records showing you did), coverage is denied.
• The drug is on a higher cost tier. Your drug may be on the formulary but placed on a higher cost-sharing tier, making it more expensive than you expected. You can request a tiering exception (42 CFR 423.578(a)).
• Quantity limits were exceeded. Your plan may limit the amount of a drug you can get in a given time period. Prescriptions that exceed these limits will be denied.

Should You Appeal?

What To Do Next

1. Check if your drug has new cost protections. Before appealing, make sure the denial isn’t a billing error for a drug that should now be cheaper or free:
   • Insulin is capped at $35 for a month’s supply of each covered insulin product under every Part D plan, a cap in place since 2023 under the Inflation Reduction Act (Medicare.gov; KFF).
   • Adult vaccines recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP) have been covered at $0 cost-sharing under Part D since January 1, 2023 (HHS ASPE).
   • Weight loss GLP-1s (Wegovy, Zepbound KwikPen, Foundayo): The Medicare GLP-1 Bridge program has covered these drugs at a $50 copay for eligible beneficiaries since July 1, 2026, and runs through December 31, 2027 (CMS). This is a separate CMS program that operates outside the Part D benefit — your doctor submits prior authorization to CMS’s central processor, not to your Part D plan. See our GLP-1 coverage guide for eligibility details.
   • If your out-of-pocket drug costs are high, ask your plan about the Medicare Prescription Payment Plan, which lets you spread your out-of-pocket costs for covered drugs across the calendar year in monthly bills instead of paying everything at the pharmacy counter.
2. Don’t leave the pharmacy empty-handed if you need the medication urgently. Ask your pharmacist about paying out of pocket for a short supply, or — if you are new to the plan or the plan changed its formulary — ask about a one-time transition fill of a drug you were already taking.
3. Contact your prescribing doctor. Tell them the drug was denied and ask them to submit a supporting statement to your plan. This is the single most important step — a prescriber’s supporting statement is required for every exception request (42 CFR 423.578).
4. Request a coverage determination or exception. You, your doctor, or someone you authorize can call or write to your Part D plan (CMS coverage determinations) to request:
   • A formulary exception (to cover a drug not on the formulary)
   • A tiering exception (to pay less for a drug on a higher cost tier)
   • A step therapy exception (to skip the requirement to try another drug first)
   • A prior authorization (to get advance approval for a restricted drug)
5. Request an expedited decision if your health is at risk. If your doctor states that waiting could seriously harm your health, the plan must decide within 24 hours instead of the standard 72 hours (42 CFR 423.572).
6. If your request is denied, appeal — and watch the deadlines, because Level 2 does not happen on its own. Your denial notice will include instructions. The first appeal (called a “redetermination”) goes back to your plan, and you have 65 days from the date on the denial notice to ask for it; the plan must answer within 7 calendar days, or 72 hours if expedited (CMS redetermination rules). If the plan upholds its denial, you must file the next appeal yourself — you have 60 days from the date you receive the plan’s redetermination decision to file a written reconsideration request with the Independent Review Entity (IRE) (42 CFR 423.600). Your plan’s decision letter will tell you where to send it. Cases move to the IRE automatically only in narrow circumstances: when your plan misses its own decision deadline, and for certain drug-management (“at-risk”) determinations (42 CFR 423.590). Do not wait for a case that will not move.
7. Get free help. Contact your State Health Insurance Assistance Program (SHIP), call 1-800-MEDICARE (1-800-633-4227), or visit Medicare.gov.

Part D Appeal Timeline

Timeframes above: coverage determinations, 42 CFR 423.568 and 423.572; redeterminations, 423.590; IRE reconsiderations, 423.600; OMHA hearings, 423.2002 and Medicare.gov.

Every level after the first requires you to file — the case does not advance by itself. The exceptions are narrow: if your plan misses its own decision deadline, the request is forwarded to the IRE for you, and certain drug-management (“at-risk”) determinations are auto-forwarded as well. If you miss the 65-day redetermination deadline, you can still file late by giving a reason for the delay (Medicare.gov) — but do not count on it.

Sources

• Medicare.gov: Appeals in a Medicare Drug Plan — the 65-day redetermination deadline, the 7-day/72-hour plan decision window, the 60-day deadline to file with the Part D IRE, the IRE’s 7-day/14-day/72-hour decision windows, the 60-day Level 3 window, and filing late with a reason
• 42 CFR 423.568 — standard coverage determinations: 72 hours for a drug benefit or exception request (the exception clock runs from receipt of the prescriber’s supporting statement, and if no statement arrives within 14 calendar days the 72-hour (24-hour expedited) clock runs from the end of that period); 14 calendar days for a request for payment; a missed deadline is forwarded to the IRE
• 42 CFR 423.572 — expedited coverage determinations: 24 hours, likewise measured from the supporting statement
• 42 CFR 423.578 — tiering and formulary exceptions; the prescriber’s supporting statement that the preferred or formulary drugs would not be as effective or would have adverse effects
• 42 CFR 423.590 — redeterminations: 7 calendar days standard, 14 calendar days for payment, 72 hours expedited; a missed deadline is itself an adverse decision the plan must forward to the IRE; at-risk determinations are auto-forwarded
• 42 CFR 423.600 — the enrollee (or prescriber) must file a written reconsideration request with the IRE within 60 calendar days of receiving the plan’s redetermination; the IRE decides on the same timeframes as 423.590
• 42 CFR 423.2002 — ALJ hearing request within 60 calendar days of receiving the IRE decision, subject to the amount-in-controversy requirement
• 42 CFR 423.120(b)(3) — the transition process: a one-time temporary fill of at least a month’s supply for new enrollees and for current enrollees affected by formulary changes
• CMS: Part D Coverage Determinations — who can request one; the 72-hour/24-hour decision windows; the 14-day payment window
• CMS: Part D Exceptions — what the prescriber’s supporting statement must show
• CMS: Redetermination by the Part D Plan Sponsor — 7 calendar days standard, 72 hours expedited
• CMS: Part D Plan Sponsor Notices — the pharmacy notice “Medicare Drug Coverage and Your Rights” (CMS-10147)
• Medicare.gov: Drug Plan Rules — prior authorization, step therapy, quantity limits, and the one-time 30-day transition fill
• Medicare.gov: Insulin — no more than $35 for a one-month supply of each covered insulin product
• KFF: Changes to Medicare Part D under the Inflation Reduction Act — the $35 insulin cap in place since 2023; adult vaccines with no cost sharing
• HHS ASPE: Elimination of Vaccine Cost-Sharing — ACIP-recommended adult vaccines under Part D have had no cost sharing since January 1, 2023
• CMS: Medicare GLP-1 Bridge — July 1, 2026 through December 31, 2027; $50 copay; operates outside the Part D benefit with a central processor for prior authorization
• Medicare.gov: Medicare Prescription Payment Plan — spreading out-of-pocket costs for covered drugs across the calendar year

Frequently Asked Questions